Ketamine Troches for Fibromyalgia

Ketamine troches for fibromyalgia use low, sub-dissociative doses of ketamine dissolved under the tongue to reduce the amplified pain signaling that defines the condition. Fibromyalgia affects an estimated 2 to 4 percent of the population, predominantly women, and produces widespread musculoskeletal pain, fatigue, sleep disturbance, and cognitive difficulties often called "fibro fog." Despite decades of research, the condition remains difficult to manage with conventional medication alone. Researchers now understand the central driver of fibromyalgia to be central sensitization, a state in which the brain and spinal cord become hyperresponsive to stimuli and amplify pain signals beyond what any peripheral tissue damage would explain. This is why patients feel pain from touch that would not hurt a healthy person, known as allodynia, and exaggerated pain from mildly painful stimuli, known as hyperalgesia. Ketamine's primary analgesic action, NMDA receptor blockade in the spinal cord and brain, targets this mechanism directly, which is why clinicians consider ketamine troches for fibromyalgia a pharmacologically rational option when standard treatments fall short. For background on how sublingual dosing works across conditions, see our sublingual ketamine therapy guide.

Fibromyalgia as a Central Sensitization Syndrome

Central sensitization is a state in which the central nervous system, meaning the brain and spinal cord, becomes hyperresponsive to sensory input and amplifies pain beyond what tissue damage would predict. Fibromyalgia's tender points, widespread pain, and fatigue stem largely from this process rather than from ongoing damage in the muscles or joints themselves, based on mechanisms described in the StatPearls clinical reference on ketamine pharmacology. Because ketamine's primary mechanism is NMDA receptor blockade at spinal and supraspinal levels, it acts directly on the pathway believed to sustain fibromyalgia pain, rather than only masking symptoms peripherally the way many standard analgesics do.

How Ketamine Targets Fibromyalgia Mechanisms

Reducing Spinal Cord Wind-Up

The spinal cord dorsal horn is a key site of pain amplification in fibromyalgia. Repeated stimulation of NMDA receptors there produces the wind-up phenomenon, in which neurons fire progressively larger responses to the same stimulus. Clinical studies have found that fibromyalgia patients show significantly more wind-up than healthy controls, and ketamine's NMDA receptor blockade directly reduces this dorsal horn amplification.

Supraspinal Modulation

Fibromyalgia also involves impaired descending pain modulation, the signals the brain normally sends down to the spinal cord to inhibit pain. In fibromyalgia, inhibitory output from the periaqueductal gray and rostral ventromedial medulla is reduced. Ketamine may help restore this balance through its NMDA receptor effects and by stimulating release of norepinephrine and serotonin, both key mediators of descending pain inhibition.

Addressing Comorbid Depression and Anxiety

Depression affects an estimated 30 to 50 percent of fibromyalgia patients, and anxiety is similarly common. Both conditions amplify how pain is experienced. Ketamine's antidepressant and anxiolytic effects, driven by its glutamatergic action, can create a synergistic benefit for patients with these comorbidities: pain relief through central sensitization modulation alongside mood improvement. According to the World Health Organization, depression affects more than 280 million people worldwide and commonly co-occurs with chronic pain conditions.

Troche Protocols for Fibromyalgia

Fibromyalgia troche protocols differ from psychiatric ketamine protocols in both dose and goal. Where psychiatric dosing often aims for a dissociative, resetting experience, fibromyalgia dosing targets analgesia with minimal dissociation.

Low-Dose Approach

• Starting dose: 50 to 100 mg
• Target dose: 100 to 200 mg, lower than typical psychiatric protocols
• Goal: Meaningful pain reduction with minimal dissociative experience

At these doses, most patients can function normally during and shortly after the session. Patients often describe mild relaxation and some emotional softening, with pain relief beginning during or shortly after dosing. For a breakdown of how sublingual ketamine is absorbed and when effects begin, see our onset, peak, and duration timeline guide.

Frequency Options

Several dosing frequencies are used in clinical practice:

• Sub-dissociative daily dosing: 50 to 100 mg daily or near-daily for consistent NMDA blockade.
• Every-other-day dosing: A middle ground between consistent coverage and minimizing frequency of use.
• Twice-weekly analgesic dosing: Similar to maintenance psychiatric protocols, offering good coverage with less daily commitment.
• Intermittent higher-dose sessions: 2 to 3 sessions per month at 150 to 250 mg for a deeper central sensitization reset, with residual benefit carrying through to the next session.

The right frequency depends on the individual's pain pattern, how long relief lasts, and the prescriber's clinical judgment. See our guide on working with your provider for how these decisions are typically made.

Evidence Base

Several studies have examined ketamine specifically for fibromyalgia, mostly using intravenous administration rather than troches.

Graven-Nielsen and colleagues (2000) found that IV ketamine reduced temporal summation, a form of wind-up, and raised pressure-pain thresholds in fibromyalgia patients, offering mechanistic evidence for NMDA receptor involvement in the condition. Noppers and colleagues (2011) ran a randomized trial comparing IV ketamine to saline in fibromyalgia patients and found pain reduction that persisted up to three months after a single five-day infusion course. Multiple open-label studies and case series report pain reductions of 30 to 60 percent in responders, with relief lasting anywhere from days to weeks per session or course.

A case report published in PubMed Central describes a 60-year-old fibromyalgia patient who, after a titrated IV infusion series, sustained more than 50 percent pain reduction on a maintenance schedule of two monthly infusions. According to that case report, fibromyalgia affects an estimated 1 to 5 percent of the U.S. population, and published ketamine dosing in the literature ranges widely, from 20 mg to 3,000 mg administered over 1 to 10 days, reflecting how unstandardized fibromyalgia ketamine protocols still are.

Limitations

• Most fibromyalgia ketamine research uses IV administration; sublingual troche data is largely extrapolated from these findings
• Response is not universal; some patients do not experience meaningful benefit
• Optimal troche dosing, frequency, and duration are not standardized across the field

To see how outcomes compare between infusion and troche delivery more broadly, read our troches versus infusion outcomes comparison.

Monitoring Response

Track fibromyalgia-specific outcomes to judge whether ketamine troches are working. A reduction in Fibromyalgia Impact Questionnaire (FIQ-R) score of 20 percent or more is generally considered a clinically meaningful response.

Realistic Expectations

Ketamine troches for fibromyalgia are not a cure. Patients who respond typically describe:

• Pain reduction of roughly 30 to 50 percent during the session and for days to weeks afterward
• Improved sleep quality correlating with dosing sessions
• Better mood and reduced fatigue
• Ability to participate in rehabilitation, such as physical therapy or exercise, that pain previously limited
• Gradual, cumulative improvement over multiple sessions

Not everyone responds. For those who do, ketamine troches become one part of a broader fibromyalgia toolkit, not a replacement for medication, exercise, sleep management, and therapy.